Drug companies advertise on TV because it works remarkably well at driving prescriptions. The United States is one of only two developed countries that allows direct-to-consumer advertising of prescription drugs (New Zealand is the other), and pharmaceutical companies took full advantage in 2024, spending over $5 billion on TV ads alone and another $5 billion on radio, print, streaming, and online ads. That $10.1 billion investment pays off because TV ads change patient behavior in ways that directly increase sales.
TV Ads Get Patients to Ask for Specific Drugs
The core business logic is straightforward: when people see a drug ad on TV, a meaningful percentage of them bring it up at their next doctor’s visit. About one in five Americans has contacted their doctor specifically because of a drug advertisement. That might sound modest, but across a population of hundreds of millions, it translates into an enormous number of new prescriptions.
What makes this especially effective is what happens once a patient walks into the exam room and asks for a specific brand. Patients who request an advertised drug are nearly 17 times more likely to leave with a prescription than patients who don’t make a request. In studies comparing the two scenarios, 71% of patients who asked for a specific drug got a prescription, compared to just 26% of those who didn’t ask. That gap is the entire reason pharmaceutical advertising exists.
Doctors Often Prescribe What Patients Request
You might assume doctors would simply redirect patients toward the best clinical option regardless of what ad they saw. In practice, that’s not what happens. Multiple physician surveys found that doctors comply with requests for advertised drugs between 39% and 77% of the time. In one FDA survey, physicians filled these requests 76% of the time, even though 64% of those same doctors reported that the ad-driven conversations offered no benefit or had a negative effect on the visit.
Perhaps more striking: in one survey, 48% of physicians said they prescribed an advertised drug even though they personally disagreed with the request. They did it to accommodate the patient. Another survey of 535 doctors found compliance rates of 77% despite nearly half the requests being deemed clinically inappropriate by the prescribing physician’s own judgment. The most common reasons doctors pushed back were cost concerns and clinical considerations, but outright refusal was the exception, not the rule.
This dynamic is what makes TV advertising so profitable. Drug companies aren’t just hoping to raise brand awareness. They’re inserting their product into a conversation between patient and doctor, and the social pressure of that conversation reliably converts into prescriptions.
Why the U.S. Allows It
Most countries ban prescription drug ads directed at consumers. Australia explicitly prohibits it by law, and the European Union has similar restrictions. The U.S. and New Zealand stand alone among developed nations in permitting the practice.
In the U.S., the FDA regulates these ads rather than banning them outright. Every TV ad for a prescription drug must include what’s called a “major statement” covering side effects and situations where the drug shouldn’t be used. The FDA requires this risk information to meet five specific standards. It must use consumer-friendly language. The audio for side effects must be spoken at the same volume, speed, and clarity as the rest of the ad. On television, risk information must appear simultaneously as both audio and on-screen text. That text must be large enough and displayed long enough to actually read. And nothing else in the ad, whether music, visuals, or distracting imagery, can interfere with the viewer’s ability to understand the risks.
These rules exist because drug companies have historically buried side effects in rapid-fire voiceovers played over footage of people hiking and laughing with their families. The regulations attempt to level the playing field between the appealing imagery selling the drug and the risk information required by law.
The Case That Ads Help Patients
Supporters of pharmaceutical advertising argue it serves a genuine public health function by alerting people to conditions they might not know they have. There’s some evidence for this. Research on cholesterol-lowering drug ads found that advertising spending had a positive, long-term effect on the number of visits to doctors by newly diagnosed patients with high cholesterol. The ads didn’t just shift patients from one brand to another. They brought new people into the healthcare system who hadn’t previously been treated.
This effect was especially pronounced among underserved populations, including people on Medicaid. For conditions that are widely underdiagnosed, like high cholesterol, depression, or diabetes, TV ads can serve as a nudge that gets someone to finally schedule an appointment. The category-expanding effect, where ads grow the total number of people seeking treatment rather than just reshuffling market share, is the strongest argument in favor of allowing the practice.
The Case That Ads Raise Costs
The most persistent criticism of pharmaceutical TV advertising is its effect on drug prices. When patients request brand-name drugs they saw on television, they’re often choosing an expensive option over a cheaper generic that works just as well. Doctors comply with these requests at high rates, which means advertising directly contributes to higher prescription costs across the system.
The $10.1 billion spent on advertising in 2024 isn’t free money. Those costs get built into drug prices, and the top 10 most-advertised drugs accounted for a third of total spending. The drugs that get the heaviest TV promotion tend to be newer, patent-protected, and expensive, precisely the ones where a generic alternative either doesn’t exist yet or where the company wants to establish brand loyalty before one arrives.
There’s also the issue of clinically inappropriate prescribing. When studies show that roughly half of ad-driven prescriptions may not be the best clinical choice for the patient, the advertising isn’t just expensive. It’s potentially steering treatment in the wrong direction. A patient who asks for a specific brand-name drug because they saw it during the evening news may end up on a medication that costs more and works no better than the alternative their doctor would have chosen unprompted.
Why TV Specifically
Drug companies concentrate on television for the same reason car companies and insurance companies do: it reaches enormous audiences, especially older adults who use the most prescription medications. Primetime network television on ABC, CBS, NBC, and FOX during evening hours remains a primary vehicle for these ads. If you’ve noticed that pharmaceutical commercials seem to dominate certain time slots, you’re not imagining it. Industry spending made up a significant share of evening advertising minutes in 2024.
The format also matters. A 60-second TV spot can pair an emotional story with a drug name in a way that print or digital ads struggle to replicate. Seeing a person who looks like you, living the life you want, crediting a specific medication creates a powerful association. The FDA’s requirement that risks be presented with equal clarity is an attempt to counterbalance this, but the emotional weight of the visual narrative almost always outweighs a list of side effects read in a neutral tone.
Streaming platforms and online video are growing as advertising channels, but traditional TV still captured roughly half of the industry’s $10.1 billion ad budget in 2024. As viewing habits shift, pharmaceutical companies are following audiences to new platforms, but the underlying strategy remains the same: put the drug’s name in your head so you bring it up with your doctor.